If you have been diagnosed with a type of non-Hodgkin's lymphoma, Bexxar® (tositumomab) may help slow down the progression of the cancer. This prescription medicine is specifically approved for use in adults whose cancer has returned or who have been unsuccessful with other treatments.
Bexxar is a monoclonal antibody. An antibody (also known as an immunoglobulin) is a protein made by the immune system. Antibodies attach to proteins found on certain molecules, marking the molecule for destruction by the immune system.
Bexxar is a synthetic (laboratory-made) antibody that binds to healthy and cancerous B-cells (a type of white blood cell). By binding to the CD20 antigen, Bexxar signals the body to destroy the B-cells. This drug is also linked to a radioactive element that emits radiation and destroys surrounding cancer cells.
(Click Bexxar for a closer look at how monoclonal antibodies can help slow down the progression of non-Hodgkin's lymphoma. This article also talks about how the drug is given, potential side effects, and how your dosage will be determined.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Bexxar [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2012 August.
Bexxar Web site. Available at: http://www.bexxar.com/. Accessed December 15, 2011.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA approved drug products. FDA Web site. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed December 15, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click